CD73分子在肿瘤中的重要作用

doi:10.3969/j.issn.1673-8640.2017.07.023

摘要/Abstract

摘要：

嘌呤在肿瘤的发展过程中扮演着重要的角色,该信号通路受到一系列核苷酸酶调控。在这些酶中,CD73是关键酶之一,可以催化磷酸腺苷（AMP）水解为腺苷,从而介导腺苷的生物学作用。目前的研究已经发现CD73高表达于多种实体肿瘤,多个因子和机制都参与CD73表达的调控。越来越多的研究发现,CD73是体外肿瘤细胞增殖、转移和侵袭,体内肿瘤血管生成和肿瘤免疫逃逸机制的关键调控分子。体内试验的证据显示,对于肿瘤患者,靶向阻断CD73将成为有效的治疗手段。文章总结了CD73在肿瘤发展过程中的重要作用,包括其对于肿瘤血管生成的促进作用、影响肿瘤生长和转移的机制、对肿瘤微环境中免疫系统的抑制效应以及未来抗CD73分子的治疗与展望。

关键词: CD73, 腺苷, 靶向治疗, 肿瘤

Abstract:

Purine plays an important role in cancer progression,and is regulated by a series of nucleotidases. CD73 is one of key enzymes. CD73 can catalyze adenosine monophosphate（AMP）breakdown to adenosine,and is found to be overexpressed in many types of cancers. There are various factors and mechanisms for regulating the expression of CD73. More and more studies have shown that CD73 is a key regulatory molecule of in vitro cancer cell proliferation,migration and invasion and in vivo tumor angiogenesis and tumor immune escape. Evidences in in vivo model prove that targeted blockade of CD73 could be a favorable therapeutic approach for cancer patients. This review will summarize the roles of CD73 in cancer development,including tumor angiogenesis,tumor growth and metastasis,suppressing the efficiency of immune response and the status of anti-CD73 cancer therapy.

Key words: CD73, Adenosine, Targeted therapy, Caneer

中图分类号:

R446.62

高姚怡, 马晓路, 吴炯综述, 郭玮, 潘柏申校审. CD73分子在肿瘤中的重要作用[J]. 检验医学, 2017, 32(7): 656-662.

GAO Yaoyi, MA Xiaolu, WU Jiong, GUO Wei, PAN Baishen. Role of CD73 in cancer[J]. Laboratory Medicine, 2017, 32(7): 656-662.

参考文献 46

[1]	BURNSTOCK G,VIRGILIO F.Purinergic signaling and cancer[J]. Purinergic Signal,2013,9(4):491-540.
[2]	HELENIUS M,JALKANEN S,YEGUTKIN G.Enzyme-coupled assays for simultaneous detection of nanomolar ATP,ADP,AMP,adenosine,inosine and pyrophosphate concentrations in extracellular fluids[J]. Biochim Biophys Acta,2012,1823(10):1967-1975.
[3]	ALLARD B,BEAVIS P A,DARCY P K,et al.Immunosuppressive activities of adenosine in cancer[J]. Curr Opin Pharmacol,2016,29:7-16.
[4]	YEGUTKIN G G.Nucleotide- and nucleoside-converting ectoenzymes:important modulators of purinergic signaling cascade[J]. Biochim Biophys Acta,2008,1783(5):673-694.
[5]	STAGG J,SMYTH M J.Extracellular adenosine triphosphate and adenosine in cancer[J]. Oncogene,2010,29(39):5346-5358.
[6]	GHIRINGHELLI F,BRUCHARD M,CHALMIN F,et al.Production of adenosine by ectonucleotidases:a key factor in tumor immuno-escape[J]. J Biomed Biotechnol,2012,2012:473712.
[7]	ZHI X,CHEN S,ZHOU P,et al.RNA interference of ecto-5′-nucleotidase(CD73)inhibits human breast cancer cell growth and invasion[J]. Clin Exp Metastasis,2007,24(6):439-448.
[8]	ZHANG B.CD73 promotes tumor growth and metastasis[J]. Oncoimmunology,2012,1(1):67-70.
[9]	WANG L,TANG S,WANG Y,et al.Ecto-5'-nucleotidase(CD73)promotes tumor angiogenesis[J]. Clin Exp Metastasis,2013,30(5):671-680.
[10]	ANTONIOLI L,YEGUTKIN G G,PACHER P,et al.Anti-CD73 in cancer immunotherapy:awakening new opportunities[J]. Trends Cancer,2016,2(2):95-109.
[11]	ALLARD B,TURCOTTE M,SPRING K,et al.Anti-CD73 therapy impairs tumor angiogenesis[J]. Int J Cancer,2014,134(6):1466-1473.
[12]	BÖRING Y C,FLÖGEL U,JACOBY C,et al. Lack of ecto-5'-nucleotidase(CD73)promotes arteriogenesis[J]. Cardiovasc Res,2013,97(1):88-96.
[13]	GIULIANO S,PAGES G.Mechanisms of resistance to anti-angiogenesis therapies[J]. Biochimie,2013,95(6):1110-1119.
[14]	ZHI X,WANG Y,ZHOU X,et al.RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells[J]. Cancer Sci,2010,101(12):2561-2569.
[15]	ZHOU X,ZHI X,ZHOU P,et al.Effects of ecto-5'-nucleotidase on human breast cancer cell growth in vitro and in vivo[J]. Oncol Rep,2007,17(6):1341-1346.
[16]	SHIRALI S,AGHAEI M,SHABANI M,et al.Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3[J]. Tumour Biol,2013,34(2):1085-1095.
[17]	ZHI X,WANG Y,YU J,et al.Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer[J]. IUBMB Life,2012,64(11):911-920.
[18]	YEGUTKIN G G,MARTTILA-ICHIHARA F,KARIKOSKI M,et al.Altered purinergic signaling in CD73-deficient mice inhibits tumor progression[J]. Eur J Immunol,2011,41(5):1231-1241.
[19]	KOSZALKA P,GOLUNSKA M,STANISLA-WOWSKI M,et al.CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth,angiogenesis,neovascularization,macrophage infiltration and metastasis[J]. Int J Biochem Cell Biol,2015,69:1-10.
[20]	SADEJ R,SPYCHALA J,SKLADANOWSKI A C.Ecto-5'-nucleotidase(eN,CD73)is coexpressed with metastasis promoting antigens in human melanoma cells[J]. Nucleosides Nucleotides Nucleic Acids,2006,25(9-11):1119-1123.
[21]	XIONG L,WEN Y,MIAO X,et al.NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition(EMT)are associated with tumor progression and survival of patients with gallbladder cancer[J]. Cell Tissue Res,2014,355(2):365-374.
[22]	SADEJ R,SKLADANOWSKI A C.Dual,enzymatic and non-enzymatic,function of ecto-5'-nucleotidase(eN,CD73)in migration and invasion of A375 melanoma cells[J]. Acta Biochim Pol,2012,59(4):647-652.
[23]	STAGG J,DIVISEKERA U,DURET H,et al.CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis[J]. Cancer Res,2011,71(8):2892-2900.
[24]	WANG L,ZHOU X,ZHOU T,et al.Ecto-5'-nucleotidase promotes invasion,migration and adhesion of human breast cancer cells[J]. J Cancer Res Clin Oncol,2008,134(3):365-372.
[25]	LU X X,CHEN Y T,FENG B,et al.Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma[J]. World J Gastroenterol,2013,19(12):1912-1918.
[26]	ANTONIOLI L,PACHER P,VIZI E S,et al.CD39 and CD73 in immunity and inflammation[J]. Trends Mol Med,2013,19(6):355-367.
[27]	BEAVIS P A,STAGG J,DARCY P K,et al.CD73:a potent suppressor of antitumor immune responses[J]. Trends Immunol,2012,33(5):231-237.
[28]	KUMAR V.Adenosine as an endogenous immuno-regulator in cancer pathogenesis:where to go?[J]. Purinergic Signal,2012,9(2):145-165.
[29]	RASKOVALOVA T,HUANG X,SITKOVSKY M,et al.GS protein-coupled adenosine receptor signaling and lytic function of activated NK cells[J]. J Immunol,2005,175(7):4383-4391.
[30]	NOVITSKIY S V,RYZHOV S,ZAYNAGETDINOV R,et al.Adenosine receptors in regulation of dendritic cell differentiation and function[J]. Blood,2008,112(5):1822-1831.
[31]	WHITESIDE T L,MANDAPATHIL M,SCHULER P.The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells(Treg)[J]. Curr Med Chem,2011,18(34):5217-5223.
[32]	RYZHOV S,NOVITSKIY S V,GOLDSTEIN A E,et al.Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+cells[J]. J Immunol,2011,187(11):6120-6129.
[33]	UJHÁZY P,BERLETH E S,PIETKIEWICZ J M,et al. Evidence for the involvement of ecto-5'-nucleotidase(CD73)in drug resistance[J]. Int J Cancer,1996,68(4):493-500.
[34]	QUEZADA C,GARRIDO W,OYARZÚN C,et al. 5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiform cells[J]. J Cell Physiol,2013,228(3):602-608.
[35]	LOI S,POMMEY S,HAIBE-KAINS B,et al.CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer[J]. Proc Natl Acad Sci U S A,2013,110(27):11091-11096.
[36]	JIN D,FAN J,WANG L,et al.CD73 on tumor cells impairs antitumor T-cell responses:a novel mechanism of tumor-induced immune suppression[J]. Cancer Res,2010,70(6):2245-2255.
[37]	SEMENZA G L.Hypoxia-inducible factor 1:Regulator of mitochondrial metabolism and mediator of ischemic preconditioning[J]. Biochim Biophys Acta,2011,1813(7):1263-1268.
[38]	BRISEVAC D,BJELOBABA I,BAJIC A,et al.Regulation of ecto-5'-nucleotidase(CD73)in cultured cortical astrocytes by different inflammatory factors[J]. Neurochem Int,2012,61(5):681-688.
[39]	GAUDREAU P O,ALLARD B,TURCOTTE M,et al.CD73-adenosine reduces immune responses and survival in ovarian cancer patients[J]. Oncoimmunology,2016,5(5):e1127496.
[40]	LO NIGRO C,MONTEVERDE M,LEE S,et al.NT5E CpG island methylation is a favourable breast cancer biomarker[J]. Br J Cancer,2012,107(1):75-83.
[41]	THOM V T,WENDEL M,DEUSSEN A.Regulation of ecto-5'-nucleotidase by docosahexaenoic acid in human endothelial cells[J]. Cell Physiol Biochem,2013,32(2):355-366.
[42]	HÄUSLER S F,DEL BARRIO I M,DIESSNER J,et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion[J]. Am J Transl Res,2014,6(2):129-139.
[43]	STAGG J,DIVISEKERA U,MCLAUGHLIN N,et al.Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis[J]. Proc Natl Acad Sci U S A,2010,107(4):1547-1552.
[44]	PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer,2012,12(4):252-264.
[45]	ALLARD B,POMMEY S,SMYTH M J,et al.Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs[J]. Clin Cancer Res,2013,19(20):5626-5635.
[46]	LANNONE R,MIELE L,MAIOLINO P,et al.Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model[J]. Am J Cancer Res,2014,4(2):172-181.